Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  Central Coast Health Watch  -  Page 82

Dignity Health
Latest

FDA fast tracks Amgen’s Blincyto leukemia drug

By   /  Thursday, March 30th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on FDA fast tracks Amgen’s Blincyto leukemia drug

Thousand Oaks-based biotech giant Amgen announced March 29 that the U.S. Food and Drug Administration has fast-tracked the company’s leukemia drug Blincyto for priority review. The drug increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. It almost doubled median overall survival versus chemotherapy among adult patients Read More →

Read More →
Latest

Law firm probing Sientra board of directors

By   /  Friday, March 24th, 2017  /  Central Coast Health Watch, Latest news, Law  /  Comments Off on Law firm probing Sientra board of directors

The law firm of Brodsky & Smith has announced an investigation into the board of directors at Sientra, a breast implant manufacturing firm based in Goleta. According to a news release from the law firm, the investigation comes after previous litigation. The complaint alleges that the defendants made false and misleading statements, including failing to Read More →

Read More →
Latest

500 Amgen employees to be re-assigned, relocated or laid off

By   /  Friday, March 24th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Economy  /  Comments Off on 500 Amgen employees to be re-assigned, relocated or laid off

Nearly 500 Amgen employees in Thousand Oaks have been notified that they will be re-assigned, relocated or laid off as part of a restructuring plan. The biotech giant informed employees on March 22 that they will be reassigned to a new Tampa Bay, Fla. facility and research and development offices in Cambridge, Mass. and South Read More →

Read More →
Latest

Amgen gets European approval for biosimilar of Humira

By   /  Friday, March 24th, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen gets European approval for biosimilar of Humira

Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →

Read More →
Latest

Tri-county hospitals oppose Trump health care bill

By   /  Friday, March 24th, 2017  /  Central Coast Health Watch, Latest news, Technology, Tri-County Economy  /  Comments Off on Tri-county hospitals oppose Trump health care bill

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Hospitals upgrade emergency facilities to meet demand

By   /  Friday, March 24th, 2017  /  Central Coast, Central Coast Health Watch, middle, Technology  /  Comments Off on Hospitals upgrade emergency facilities to meet demand

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Breast implant maker Sientra battles its way back

By   /  Friday, March 17th, 2017  /  Central Coast Health Watch, South Coast, Technology, Top Stories, Top Story  /  Comments Off on Breast implant maker Sientra battles its way back

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →